We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 60,335 | 08:00:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
| Date | Subject | Author | Discuss |
|---|---|---|---|
| 28/9/2020 14:50 | >> njb67 Good to hear from you! And it is also good to hear that you think SNG001 looks promising. What are your thoughts on the possibility of emergency use approval on the back of the phase II data? | nobbygnome | |
| 28/9/2020 14:49 | Yep. Might dump if the poor share price performance continues for many more weeks although I'm reluctant to do so for the time being. | investordave | |
| 28/9/2020 14:46 | SloppyJoe 13600 The government, including health ministers, have no say in the licensing of medicines in the UK. Licence applications are reviewed by the MHRA, who act at arms length from government. They will be the ones who will decide if SNG get a licence for the treatment of Covid. I would expect this application to be fast tracked through MHRA review, but it still takes time to a) put the submission together and b) MHRA to review it and make a decision. Vallance also has no say over what medicines are licensed in the UK, he is an advisor to government and does not work for MHRA, so there is no conflict of interest here at all. Drug looks very promising btw. | njb67 | |
| 28/9/2020 14:34 | SNG is effectively down over 11p today, it's looking quite bleak on an otherwise strong day on the market. | festario |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
